COLL stock: buy or sell?
February 27th, 2020
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.
Should I buy COLL stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Collegium Pharmaceutical stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Collegium Pharmaceutical stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for COLL stock for the last month.
COLL stock analysis
Collegium Pharmaceutical shares collapsed -3.94% to $21.68 today.
Collegium Pharmaceutical collapsed a frightening -3.94% and closed at $21.68. Since SMA100d and SMA200d crossed up on December, COLL price climbed $0.73 per share (3.48%). Since last November when COLL stock price broke up the SMA200d line, it gained $8.83 (68.72%).
Shares of Collegium Pharmaceutical closed this week at $21.68 and plunged a scary -9.40%. Early February COLL skyrocketed a super good 20.94% in just one week.
In a weekly time frame, Collegium Pharmaceutical stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, COLL might consolidate in a flat-base, waiting to break out over or down under . Early December, SMA20w and SMA40w crossed up triggering a rise of 2.94%. Since early November 2019 when COLL stock price broke up the SMA40w line, it gained $8.83 (68.72%).
COLL stock price history
COLL IPO was on May 7th, 2015 at $12.00 per share1. Since then, COLL stock grew a 80.70%, with an average of 20.20% per year. If you had invested right after COLL's IPO a $1,000 in COLL stock in 2015, it would worth $807.00 today.
1: Adjusted price after possible price splits or reverse-splits.
COLL stock historical price chart
COLL stock reached 52-week highs on February 7th at $25.59, and all-time highs 2015-12-30 with a price of 30.58.
COLL stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' COLL stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price target for Collegium Pharmaceutical stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when Collegium Pharmaceutical presented its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will update this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Collegium Pharmaceutical annual turnover climbed an extraordinary 884.73% to $280.41 M dollars from $28.48 marked in 2017. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) climbed a 248.95% to -13.95%.
|2016||$1.71 M||-||$-94.18 M-5504.1%||-|
|2017||$28 M||1,564.29%||$-74.87 M-262.9%||-20.51%|
|2018||$280 M||884.73%||$-39.13 M-14.0%||-47.74%|
Quarterly financial resultsCollegium Pharmaceutical posted $73.43 million in revenues for 2018-Q4, a 4.63% improvement compared to previous quarter. Reported quarter income marked $9.09 million with a profit margin of 12.37%. Profit margin rocketed a 35.89% compared to previous quarter when profit margin was -23.52%. When comparing revenues to same quarter last year, Collegium Pharmaceutical sales marked an astounding growth and boosted a 580.26%.
|2017-Q1||$2 M||-||$-23.08 M-1063.6%||-|
|2017-Q2||$4 M||64.06%||$-21.12 M-593.3%||-8.49%|
|2017-Q3||$12 M||235.67%||$-13.26 M-111.0%||-37.20%|
|2017-Q4||$11 M||-9.67%||$-17.40 M-161.2%||31.21%|
|2018-Q1||$64 M||490.60%||$-18.65 M-29.3%||7.18%|
|2018-Q2||$73 M||14.61%||$-13.06 M-17.9%||-29.98%|
|2018-Q3||$70 M||-3.95%||$-16.50 M-23.5%||26.36%|
|2018-Q4||$73 M||4.63%||$9.09 M12.4%||-155.06%|
Collegium Pharmaceutical ownershipWhen you are planning to buy a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Collegium Pharmaceutical, 2.06% of all outstanding shares are owned by its staff.
Bearish positions for COLL stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Collegium Pharmaceutical:
|Market cap||$726.9 M|
|Total shares||33.5 M|
|Float shares||32.9 M|
|- Institutional holdings (%)||99.8%|
|- Insider holdings (%)||2.1%|
|Shares in short selling||0.0%|
|Thursday, February 27th, 2020|
|Day range||$21.61 - $22.47|
|Average true range||$1.78|
|50d mov avg||$21.78|
|100d mov avg||$19.01|
|200d mov avg||$15.31|
Collegium Pharmaceutical performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked as the bechmarking frame for Collegium Pharmaceutical stock.